GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Current Ratio

StageZero Life Sciences (StageZero Life Sciences) Current Ratio : 0.04 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. StageZero Life Sciences's current ratio for the quarter that ended in Sep. 2023 was 0.04.

StageZero Life Sciences has a current ratio of 0.04. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If StageZero Life Sciences has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for StageZero Life Sciences's Current Ratio or its related term are showing as below:

SZLSF' s Current Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.18   Max: 8.68
Current: 0.04

During the past 13 years, StageZero Life Sciences's highest Current Ratio was 8.68. The lowest was 0.04. And the median was 0.18.

SZLSF's Current Ratio is ranked worse than
99.58% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.245 vs SZLSF: 0.04

StageZero Life Sciences Current Ratio Historical Data

The historical data trend for StageZero Life Sciences's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Current Ratio Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.09 1.30 0.50 0.04

StageZero Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.04 0.04 0.06 0.04

Competitive Comparison of StageZero Life Sciences's Current Ratio

For the Diagnostics & Research subindustry, StageZero Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Current Ratio distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Current Ratio falls into.



StageZero Life Sciences Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

StageZero Life Sciences's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=0.266/7.026
=0.04

StageZero Life Sciences's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=0.295/8.27
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StageZero Life Sciences  (OTCPK:SZLSF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


StageZero Life Sciences Current Ratio Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences (StageZero Life Sciences) Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.